Free tool
FAERS Monitor: Velcade
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021602 or its brand name (Velcade, Bortezomib). Reports on generic versions are filed under their own applications.
Reports
89,988
Serious
75,667
84% of reports
Hospitalization
28,650
Death reported
14,182
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- plasma cell myeloma9,241
- neuropathy peripheral6,529
- off label use6,498
- diarrhoea5,237
- fatigue4,581
- death4,220
- pneumonia4,108
- drug ineffective3,816
- thrombocytopenia3,761
- nausea3,129
- pyrexia2,898
- neutropenia2,749
- anaemia2,718
- rash2,472
- disease progression2,458
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 486 |
| 2005 | 906 |
| 2006 | 949 |
| 2007 | 930 |
| 2008 | 1,285 |
| 2009 | 1,463 |
| 2010 | 1,604 |
| 2011 | 2,045 |
| 2012 | 3,007 |
| 2013 | 2,560 |
| 2014 | 2,551 |
| 2015 | 8,052 |
| 2016 | 4,697 |
| 2017 | 4,756 |
| 2018 | 5,415 |
| 2019 | 6,400 |
| 2020 | 7,052 |
| 2021 | 7,529 |
| 2022 | 7,188 |
| 2023 | 6,712 |
| 2024 | 5,857 |
| 2025 | 4,910 |
| 2026 | 3,634 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,964,171 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| plasma cell myelomaSignal | 9,241 | 72.2 | 70.6 | 496,249 |
| neuropathy peripheralSignal | 6,529 | 17.1 | 16.7 | 92,890 |
| thrombocytopeniaSignal | 3,761 | 8.1 | 7.8 | 22,732 |
| disease progressionSignal | 2,458 | 4.9 | 4.7 | 7,596 |
| neutropeniaSignal | 2,749 | 4.8 | 4.6 | 8,158 |
| anaemiaSignal | 2,718 | 3.4 | 3.2 | 4,491 |
| pneumoniaSignal | 4,108 | 3.0 | 2.9 | 5,457 |
| pyrexia | 2,898 | 2.0 | 1.9 | 1,385 |
| diarrhoea | 5,237 | 1.9 | 1.9 | 2,298 |
| off label use | 6,498 | 1.7 | 1.7 | 2,117 |
| fatigue | 4,581 | 1.4 | 1.3 | 489 |
| rash | 2,472 | 1.3 | 1.3 | 202 |
| death | 4,220 | 1.1 | 1.1 | 81 |
| nausea | 3,129 | 0.9 | 0.9 | 20 |
| drug ineffective | 3,816 | 0.7 | 0.7 | 631 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.